Appendix A

Claim Amendments

1. (Currently amended) ~~Method~~ A method for treating or preventing a respiratory disease in a patient, which patient is a child and the method ~~comprising~~ comprises administering to the patient a dose of a composition containing ciclesonide, or a pharmaceutically acceptable salt, ~~solvates~~ solvate or physiologically functional derivative thereof, wherein the dose of the composition comprises ciclesonide in an amount of from 20 to 200 µg.

2. (Currently amended) ~~Method~~ The method according to claim 1, wherein the dose comprises 20, 40, 60, 80, 100, 120, 140, 160, 180 or 200 µg of ciclesonide.

3. (Currently amended) ~~Method~~ The method according to claim 1, wherein the dose comprises 40, 80 or 160 µg of ciclesonide.

4. (Currently amended) ~~Method~~ The method according to claim 1, wherein the child is a pre-pubertal human.

5. (Currently amended) ~~Method~~ The method according to claim 1, wherein the child is a human from 6 to 12 years of age.

6. (Currently amended) ~~Method~~ The method according to claim 1, wherein the dose is a daily dose in a continuous treatment regimen.

7. (Currently amended) ~~Method~~ The method according to claim 6, wherein the treatment period is more than one day.

8. (Currently amended) ~~Method~~ The method according to claim 7, wherein the treatment period is more than one week.

9. (Currently amended) ~~Method~~ The method according to claim 1, which has no effect on growth rate of the patient.

10. (Currently amended) ~~Method~~ The method according to claim 1, wherein the composition comprises a pharmaceutically acceptable carrier and/or one or more excipients.

11. (Currently amended) ~~Method~~ The method according to claim 1 wherein ciclesonide is selected from the group consisting of [11β,16α(R)]--16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna- 1,4-dien-3,20-dion, [11β,16α(S)]--16,17-[(Cyclohexylmethylen)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxoprop-oxy)pregna-1,4-dien3,20-dion, [11β,16α(R,S)]-16,17-[(Cyclohexyl-methyl-en)bis(oxy)]-11-hydroxy-21-(2-methyl-1-oxoprop-oxy)pregna-1,4-dien3,20-dion, 16α,17-(22R)-Cyclohexylmethylendioxy-11β,21-dihydroxy-

pregna-1,4-dien-3,20-dion, 16α,17-(22S)-Cyclohexylmethylendioxy-11β,21-dihydroxy-pregna-1,4-dien-3,20-dion and 16α,17-(22R,S)-Cyclohexylmethylendioxy-11β,21-dihydroxy-pregna-1,4-dien-3,20-dion.

12. (Currently amended) ~~Method~~ The method according to claim 1, comprising a once daily dosage regimen.

13. (Currently amended) ~~Method~~ The method according to claim 1, wherein the composition is suitable for administration by inhalation.

14. (Currently amended) ~~Method~~ The method according to claim 13 wherein the composition is a pharmaceutical aerosol formulation comprising a therapeutically effective amount of ciclesonide and a hydrofluorocarbon propellant~~, preferably selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof,~~ and cosolvent in an amount effective to solubilize ciclesonide and optionally a surfactant.

15. (Currently amended) ~~Method~~ The method according to claim 14, wherein the cosolvent is ethanol.

16. (Currently amended) ~~Method~~ The method according to claim 13 wherein the composition is a pharmaceutical aerosol formulation comprising particles of ciclesonide in a therapeutically effective amount and a hydrofluorocarbon propellant~~,~~

~~preferably selected from 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and a mixture thereof,~~ and 0.01 to 5 % w/w based upon propellant of polar cosolvent and optionally a surfactant.

17. (Currently amended) ~~Method~~ The method according to claim 13 wherein the composition is a dry powder and the carrier is a saccharide.

18. (Currently amended) ~~Method~~ The method according to claim 13 wherein the carrier is lactose monohydrate.

19. (Currently amended) ~~Method~~ The method according to claim 1, wherein the ~~clinical condition~~ respiratory disease is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic bronchitis, [[and]] wheezy bronchitis, emphysema, respiratory tract infection, [[and]] upper respiratory tract disease, rhinitis, and allergic and seasonal rhinitis.

20. (Currently amended) ~~Method~~ The method according to claim 1, wherein the ~~clinical condition~~ respiratory disease is mild or moderate asthma.

21. (Currently amended) ~~Method~~ The method according to claim 1, wherein the ciclesonide consists essentially ~~consists~~ of R epimer.

22. - 42. (Canceled)

43. (New) The method according to claim 14 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.

44. (New) The method according to claim 16 wherein the hydrofluorocarbon propellant is selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane and mixtures thereof.